Faculty profile

Nadia Fairbairn

ResearcherSocial MedicineUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Nadia Fairbairn

Researcher

Social Medicine

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
47 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2026.
Supervised 2 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

119

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Opioid Use Disorder Addiction Substance Use Contingency Management Health Incentives Incentivized Treatment Overdose Crisis People Who Use Drugs

Latest papers

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis.
The International journal on drug policy · 2026
Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.
Addiction (Abingdon, England) · 2026
An application of hospital at home for precariously housed people who use drugs in a community-based harm reduction setting in Vancouver, Canada.
Addiction science & clinical practice · 2026

All 119 publications

Latest funding

Engagement-focused contingency management for the treatment of opioid use disorder: a randomized controlled trial
CIHR · 2026 · Nominated PI
$910,350
Enhancing evidence-based opioid use disorder care by evaluating the real-world impact of system-level reforms in British Columbia using innovative quasi-experimental designs
CIHR · 2025 · Supervisor
$108,500
Canadian Research Initiative in Substance Misuse: BC Node
CIHR · 2022 · Principal investigator
$2,400,000

All 17 grants and awards

119 publications.

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis.

Young S, Raboud J, Dodd Z, Barnett-Tapia C, Gomes T, Fairbairn N, Bayoumi AM

The International journal on drug policy2026

DOI: 10.1016/j.drugpo.2026.105275 PMID: 42030790

Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.

Zhou VY, Fairbairn N, Lei J, Brar R, Bach P, Socias ME

Addiction (Abingdon, England)2026

DOI: 10.1111/add.70543 PMID: 42464066

An application of hospital at home for precariously housed people who use drugs in a community-based harm reduction setting in Vancouver, Canada.

Bai P, Fairbairn N, Young S, Dick J, Drake B, Phillips J, Partridge S, Ryan A, Brooks O

Addiction science & clinical practice2026

DOI: 10.1186/s13722-026-00708-9 PMID: 42533354

Safe Supply at Insite, North America's First Supervised Consumption Site: A Case Report of Reduced Harms From the Toxic Drug Supply in a Client Prescribed Powdered Fentanyl Alternative.

Fairbairn N, Hu E, Lysyshyn M, Brar R, Holliday E

Drug and alcohol review2026First author

DOI: 10.1111/dar.70175 PMID: 42130406

Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era.

Socias ME, Lei J, Zhou V, Anand R, Cui Z, Penta S, Larochelle M, Lodi S, Fairbairn N

JAMA network open2026Senior author

DOI: 10.1001/jamanetworkopen.2026.2970 PMID: 41874507

Community Pharmacy-Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program.

Mihic T, Socias ME, McCrae K, Johnson C, Nolan S, Grant C, Sutherland C, Fairbairn N

Drug and alcohol review2026Senior author

DOI: 10.1111/dar.70062 PMID: 41186078

Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder.

Anand R, Penta S, Cui Z, Fairbairn N, Socias ME

Substance use & addiction journal2025

DOI: 10.1177/29767342241279167 PMID: 39394672

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.

Mayer S, Fairbairn N, Fowler A, Boyd J, Kerr T, McNeil R

Harm reduction journal2025

DOI: 10.1186/s12954-025-01262-4 PMID: 40615907

Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.

Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Socías ME

Substance use & addiction journal2025

DOI: 10.1177/29767342241298044 PMID: 39614597

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada.

Young S, Fairbairn N, Cui Z, Bach P, Mok WY, Budau J, Slaunwhite A, Ti L, Hayashi K, Nolan S

Addiction (Abingdon, England)2025

DOI: 10.1111/add.16760 PMID: 39871812

Something wrong or missing on this profile? Suggest a correction

Nadia Fairbairn

Research

Latest papers

Latest funding

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis.

Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.

An application of hospital at home for precariously housed people who use drugs in a community-based harm reduction setting in Vancouver, Canada.

Safe Supply at Insite, North America's First Supervised Consumption Site: A Case Report of Reduced Harms From the Toxic Drug Supply in a Client Prescribed Powdered Fentanyl Alternative.

Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era.

Community Pharmacy-Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program.

Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder.

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.

Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada.

Frequent collaborators

Kanna Hayashi

Evan Wood

Seonaid Nolan

Kanna Hayashi

Thomas Kerr

Kora DeBeck

Jan Klimas

Paxton Bach

Lianping Ti

Julio Montaner

Samantha Young

Hudson Reddon

Rolando Barrios

Jade Boyd

Cheyenne Johnson

Bernard Le Foll

Ryan Mcneil

Keith Ahamad

Jane Buxton

Zach Walsh

Amanda Slaunwhite

Lindsey Richardson

Britt Dennis

Janet Raboud

Kate Shannon

Shira Goldenberg

Danya Fast

Emily Jenkins

Joshua Edward

Eric Grafstein

Scott Harrison

Mark Lysyshyn

Mohammad Karamouzian

Tea Rosic

Nikki Bozinoff

Nadia Fairbairn

Gillian Kolla

Kimberlyn McGrail

Shira Goldenberg